SONN - Income Statement - Sonnet BioTherapeutics Holdings, Inc.

	Sep-2024	Sep-2023	Sep-2022	Sep-2021	Sep-2020	Sep-2019	Dec-2018	Dec-2017	Dec-2016	Dec-2015	Dec-2014	Dec-2013	Dec-2012	Dec-2011	Dec-2010	Dec-2009	Dec-2008
REVENUE
Revenue	18.6 K	0.1	0.3	0.5	0	40.6	30.7	41.4	41.7	42.4	0	17.5	6.9	1.5	0.1	0.7	0.2
GROSS PROFIT
Cost Of Revenue	0	11.8	93.3 K	16.6	58.3 K	7.9	29.9	39.4	38.4	14.0	0	0	2.8	0.4	11.1 K	0.7	0.2
Gross Profit	18.6 K	(11.7)	0.3	(16.2)	58.3 K	32.7	0.8	2.0	3.3	28.4	0	17.5	4.1	1.1	0.1	0	0
OPERATING INCOME
Operating Expenses	11.9	18.9	30.0	25.6	17.4	4.7	3.9	4.5	5.9	10.8	0	(23.3)	2.6	1.2	0.9	1.1	1.1
Selling, General and Administrative Expenses	6.1	7.1	8.6	8.9	7.5	2.5	3.9	4.5	5.9	7.4	0	0	2.6	1.2	0.9	2.2	2.3
Research and Development Expenses	5.7	11.8	21.4	16.6	9.9	2.2	0.2	0	0	0	0	0	0	0	0	0	0
Operating Income	(11.8)	(18.8)	(29.7)	(25.1)	(24.2)	(4.7)	(3.1)	(2.5)	(2.6)	(11.5)	0	(5.8)	(2.9)	(0.7)	(0.8)	(0.4)	(0.9)
PRE-TAX INCOME
Interest Income Expense	0	0	0	0	20.7 K	0.2	0.4	(2.6)	(2.3)	(3.5)	0	0	(0.5)	(0.2)	0.1	33.9 K	20.5 K
Total Other Income	4.4	40.1 K	52.5 K	0.1	27.3 K	(0.2)	(7.4)	(5.3)	(1.5)	3.6	0	0.5	(0.5)	(0.4)	(0.2)	(0.4)	(1.3)
Pre-Tax Income	(7.4)	(18.8)	(29.7)	(25.0)	(24.3)	(4.9)	(8.1)	(7.8)	(4.1)	(14.3)	0	(6.0)	(3.4)	(1.1)	(1.0)	(0.8)	(2.2)
NET INCOME
Tax Provision	0	0	52.5 K	22 K	6.8	0.2	(0.7)	(0.6)	0.2	(0.2)	0	0	19.2 K	14.6 K	0	0	0
Net Income	(7.4)	(18.8)	(29.8)	(25.0)	(31.1)	(5.0)	(6.9)	(6.8)	(9.1)	(12.1)	0	(6.0)	(3.2)	(1.1)	(1.0)	(0.8)	(2.2)
EPS	11.3	18.1	151	314	1.02 K	5.78 K	15.6 K	21.5 K	33.5 K	42.6 K	0	68.3 K	1.25	0.47	(0.2)	(0.5)	(1.6)

Free